Plain-English translation of NCT04912765 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether a combination of two treatments — a personalized and the immunotherapy drug — can help prevent liver cancer from coming back after surgery. The vaccine is custom-made for each patient using genetic information from their own tumor, designed to teach the immune system to recognize and fight cancer cells. This medication works alongside the vaccine to boost your body's natural cancer-fighting ability.
Even after surgery removes all visible cancer, liver cancer often returns because some cancer cells may remain hidden in the body. This trial exists to test whether a personalized immune treatment can help your body's immune system find and destroy these remaining cells before they grow into new tumors.
You likely qualify if…
You likely don't qualify if…
You will have surgery to remove your cancer, then blood and tumor tissue will be collected and analyzed to create your personalized vaccine. Over 20 weeks, you will receive 10 doses of the vaccine injected into your skin every 2 weeks, combined with the medication given through an IV starting at the second vaccine dose. After the vaccine doses finish, you will continue receiving the immunotherapy medication every 4 weeks for a total of 1 year of treatment. During this time, you will have regular clinic visits for blood tests and scans to monitor how well the treatment is working and to check for any side effects.
AI-generated summary from trial data · Aug 6, 2026 · Not medical advice
Singapore
Phase
Testing effectiveness
Sponsor
National Cancer Centre, Singapore
Collaborators
Bristol-Myers Squibb
Enrollment target
~60 participants
Started
April 2021
Primary completion
December 2026
Age range
21 Years and older
Last updated on clinicaltrials.gov in July 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Dr Shuting HAN
National Cancer Centre, Singapore
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.